Recent 8-K filings for CGTX

• June 4, 2026, 8:00 AM ET other material materiality 0.70 positive item 7.01item 9.01

  Cognition Therapeutics presents at Jefferies; outlines registrational path for DLB psychosis

  Cash ~$31.2M as of March 31, 2026; $25.6M remaining NIA grant funds; runway into Q2 2027.

• May 21, 2026, 7:34 AM ET regulatory materiality 0.65 positive item 8.01item 9.01

  Cognition Therapeutics completes productive FDA meeting for zervimesine in DLB psychosis

  FDA meeting held May 20, 2026 to review Phase 2 SHIMMER study results and registrational study design.

• May 7, 2026, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  Cognition Therapeutics Q1 2026 Net Loss Narrowed to $4.6M, FDA Meeting Set for May 20

  Net loss for Q1 2026 was $4.6M ($0.05/share), down from $8.5M ($0.14/share) in Q1 2025.

• March 26, 2026, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Cognition Therapeutics Reports 2025 Year-End Financial Results and Clinical Progress on Zervimesine

  Cash and equivalents $37.0M, net loss $23.5M for 2025 versus $34.0M net loss in 2024.

• March 2, 2026, 6:59 PM ET other material materiality 0.60 neutral item 8.01item 9.01

  Cognition Therapeutics advancing zervimesine for DLB psychosis after FDA Type C meeting

  Company plans to pursue registrational path for zervimesine (CT1812) to treat DLB psychosis, following FDA Type C meeting minutes.

• November 6, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Cognition Therapeutics Q3 net loss narrows to $4.9M; secures $30M offering for zervimesine development

  Net loss of $4.9M ($0.06/shr) in Q3 2025 vs $9.9M loss ($0.25/shr) in Q3 2024.

• August 28, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 9.01

  Cognition Therapeutics raises ~$30.1M via registered direct offering of 14.7M shares at $2.05/share

  Gross proceeds of $30.1M from sale of 14.7M shares at $2.05/share in a registered direct offering.

• August 26, 2025, 7:59 PM ET regulatory materiality 0.65 positive item 8.01

  Cognition Therapeutics regains Nasdaq minimum bid price compliance

  On Aug 26, 2025, Nasdaq confirmed Cognition Therapeutics regained compliance with the $1.00 minimum bid price rule.

• August 7, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Cognition Therapeutics Q2 net loss $6.7M; cash runway into Q2 2026; clinical milestones

  Net loss of $6.7M ($0.11 per share) vs. $7.0M ($0.18 per share) in Q2 2024.

• May 8, 2025, 7:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  Cognition Therapeutics: oral zervimesine cuts GA lesion growth 28.6% in Phase 2 trial

  Zervimesine-treated patients had 28.6% slower GA lesion growth rate vs placebo in Phase 2 MAGNIFY study.

• May 7, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Cognition Therapeutics Q1 net loss $8.5M; cash $16.4M; requests EOP2 for Alzheimer's

  Net loss of $8.5M ($0.14 per share) compared to $9.2M ($0.27) in Q1 2024.

• March 20, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Cognition Therapeutics reports 2024 net loss of $34M; highlights positive Phase 2 data for zervimesine

  Cash and equivalents $25.0M at Dec 31 2024; $50.0M in NIA grant funds remaining.

• March 12, 2025, 7:59 PM ET regulatory materiality 0.70 negative item 8.01

  Cognition Therapeutics gets Nasdaq extension to Sept 8, 2025; transfer to Capital Market

  Received Nasdaq extension notice on March 12, 2025, granting 180 additional days until Sept 8, 2025 to regain $1.00 minimum bid price.

• February 26, 2025, 6:59 PM ET other material materiality 0.80 positive item 8.01item 9.01

  Cognition Therapeutics passes Phase 2 futility analysis for zervimesine in geographic atrophy

  Oral zervimesine (CT1812) passed futility analysis in Phase 2 GA trial; treated patients experienced slower lesion growth vs placebo.

• December 18, 2024, 6:59 PM ET other material materiality 0.75 neutral item 8.01item 9.01

  Cognition Therapeutics releases topline data from Phase 2 COG1201 SHIMMER study

  Slide presentation on topline results from Phase 2 COG1201 SHIMMER study made available as Exhibit 99.1.

• November 13, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Cognition Therapeutics Q3 net loss $9.9M; CT1812 slows decline 95% in Alzheimer's sub-group

  Net loss $9.9M ($0.25/share) vs $6.7M ($0.22/share) in Q3 2023; cash $22M plus $53.6M NIA grants.

• September 13, 2024, 7:59 PM ET other material materiality 0.75 negative item 3.01

  Cognition Therapeutics receives Nasdaq deficiency notice for bid price below $1.00

  Deficiency letter received on September 12, 2024; stock continues trading under CGTX.

• August 8, 2024, 7:59 PM ET earnings materiality 0.90 positive item 2.02item 9.01

  Cognition Therapeutics Reports Q2 2024 Financial Results and Positive Phase 2 SHINE Trial Data

  Phase 2 SHINE trial showed ~40% mean improvement in ADAS-Cog 11 vs placebo in mild-to-moderate Alzheimer's.

• May 7, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Cognition Therapeutics Q1 net loss $9.2M; cash runway through Q2 2025; SHINE data mid-2024

  Net loss of $9.2M ($0.27/share) vs $6.2M ($0.21/share) in Q1 2023.

• March 13, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 9.01 ◈ Material Agreements

  Cognition Therapeutics raises ~$10.4M in public offering of 6.57M shares at $1.75

  Issued 6,571,428 shares of common stock at $1.75 per share; net proceeds ~$10.4M after expenses.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event other_material

10 positive 2 negative 21 neutral

source · CGTX on sec.gov